Author:
Sharifzadeh Aghil,Fasaei Bahar Nayeri,Asadi Sepideh,Fatemi Narges,Houshmandzad Mahdi,Ghaffari Mohammad Hosein
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005;41(9):1232–9.
2. Jamiu AT, Albertyn J, Sebolai OM, Pohl CH. Update on Candida krusei, a potential multidrug-resistant pathogen. Med Mycol. 2021;59(1):14–30.
3. Yadav JS, Bezawada J, Yan S, Tyagi RD, Surampalli RY. Candida krusei: biotechnological potentials and concerns about its safety. Can J Microbiol. 2012;58(8):937–52.
4. Nenoff P, Krüger C, Neumeister C, Schwantes U, Koch D. In vitro susceptibility testing of yeasts to nystatin–low minimum inhibitory concentrations suggest no indication of in vitro resistance of Candida albicans, Candida species or non-candida yeast species to nystatin. Clin Med Investig. 2016;22(3):1.
5. Sousa F, Nascimento C, Ferreira D, Reis S, Costa P. Reviving the interest in the versatile drug nystatin: a multitude of strategies to increase its potential as an effective and safe antifungal agent. Adv Drug Deliv Rev. 2023;199:114969.